394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
About this episode
The episode discusses Eli Lilly's busy deal-making, Merck's acquisition of Terns, and the ongoing relevance of off-the-shelf CAR-T therapies.
On this week’s episode of "The Readout LOUD": Allison DeAngelis is still away, leaving Elaine Chen and Adam Feuerstein to mind the podcasting store. You've been warned. Eli Lilly’s deal man Jake van Naarden is very, very busy, so what does that mean for biotech and pharma? Speaking of deals, Merck is buying Terns for nearly $7 billion. Why are some people mad about it? You might be surprised to hear this, but off-the-shelf CAR-T therapies for cancer are still a thing. We preview an interesting data readout coming soon from Allogene Therapeutics. And finally, someone forgot to tell Wave Life Sciences that weight loss drugs are supposed to help people lose weight.
People in this episode
Hosts: Elaine Chen, Adam Feuerstein
Topics covered
- biotech
- pharma
- deals
- CAR-T therapies
- cancer treatment
- Eli Lilly
- Merck acquisition
Keywords
- Eli Lilly
- Merck
- Terns
- Allogene Therapeutics
- CAR-T
- biotech deals
- cancer therapies
- Wave Life Sciences
Mentioned in this episode
Organizations: Eli Lilly, Merck, Terns, Allogene Therapeutics, Wave Life Sciences
More episodes of The Readout Loud
- 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
- 396: A new trick for old science, and biotech VCs' scrambled playbook
- 395: Biotech investors' plea to Trump, and a busy M&A week
- 393: A conversation with the 'godfather' of biotech
- 392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.